CNB-CSIC开发的MVA-CoV2-S疫苗具有高度免疫原性,对SARS-CoV-2/COVID-19完全有效:未来和机遇

Q Pharmacology, Toxicology and Pharmaceutics
J. García-Arriaza, Mariano Esteban Rodríguez
{"title":"CNB-CSIC开发的MVA-CoV2-S疫苗具有高度免疫原性,对SARS-CoV-2/COVID-19完全有效:未来和机遇","authors":"J. García-Arriaza, Mariano Esteban Rodríguez","doi":"10.53519/analesranf.2022.88.05.08","DOIUrl":null,"url":null,"abstract":"The appearance of a new emerging virus at the end of 2019, later identified as SARS-CoV-2, which rapidly spread to the human population causing the COVID-19 pandemic (with more than 639 million people infected and more than 6.6 million deaths by November 2022), was a great challenge for science, with serious consequences for the human health system and global economy. In record time, different types of vaccines were produced that demonstrated their safety and efficacy in clinical trials and whose administration to the population has been essential for curbing the pandemic, avoiding infections, hospitalizations and deaths. Our laboratory at the CNB-CSIC has been very active in this race, generating a vaccine candidate based on the poxvirus vector termed modified vaccinia virus Ankara (MVA), which demonstrated in three animal models (mouse, hamster and rhesus macaque) its high safety, robust immunogenicity and full efficacy against SARS-CoV-2 infection. This article describes the steps that we follow it up from the beginning of the pandemic to culminate in the industrial development of a very promising vaccine candidate. The next phase is clinical trials in humans. We also discuss about other vaccines, future and opportunities in the medium-long term.\n\nKeywords: MVA; SARS-CoV-2/COVID-19: vaccine; immunogenicity; efficacy; animal models","PeriodicalId":50795,"journal":{"name":"Anales De La Real Academia Nacional De Farmacia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The MVA-CoV2-S vaccine developed at the CNB-CSIC is highly immunogenic and completely effective against SARS-CoV-2/COVID-19: future and opportunities\",\"authors\":\"J. García-Arriaza, Mariano Esteban Rodríguez\",\"doi\":\"10.53519/analesranf.2022.88.05.08\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The appearance of a new emerging virus at the end of 2019, later identified as SARS-CoV-2, which rapidly spread to the human population causing the COVID-19 pandemic (with more than 639 million people infected and more than 6.6 million deaths by November 2022), was a great challenge for science, with serious consequences for the human health system and global economy. In record time, different types of vaccines were produced that demonstrated their safety and efficacy in clinical trials and whose administration to the population has been essential for curbing the pandemic, avoiding infections, hospitalizations and deaths. Our laboratory at the CNB-CSIC has been very active in this race, generating a vaccine candidate based on the poxvirus vector termed modified vaccinia virus Ankara (MVA), which demonstrated in three animal models (mouse, hamster and rhesus macaque) its high safety, robust immunogenicity and full efficacy against SARS-CoV-2 infection. This article describes the steps that we follow it up from the beginning of the pandemic to culminate in the industrial development of a very promising vaccine candidate. The next phase is clinical trials in humans. We also discuss about other vaccines, future and opportunities in the medium-long term.\\n\\nKeywords: MVA; SARS-CoV-2/COVID-19: vaccine; immunogenicity; efficacy; animal models\",\"PeriodicalId\":50795,\"journal\":{\"name\":\"Anales De La Real Academia Nacional De Farmacia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anales De La Real Academia Nacional De Farmacia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53519/analesranf.2022.88.05.08\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anales De La Real Academia Nacional De Farmacia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53519/analesranf.2022.88.05.08","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

2019年底出现了一种新出现的病毒,后来被确定为SARS-CoV-2,它迅速传播到人群中,导致COVID-19大流行(到2022年11月,已有超过6.39亿人感染,660多万人死亡),这对科学来说是一个巨大的挑战,对人类卫生系统和全球经济造成了严重后果。在创纪录的时间内,生产出了不同类型的疫苗,这些疫苗在临床试验中证明了它们的安全性和有效性,对人群的接种对于遏制大流行、避免感染、住院和死亡至关重要。我们在CNB-CSIC的实验室在这场竞赛中非常活跃,以痘病毒载体为基础产生了一种候选疫苗,称为修饰痘苗病毒安卡拉(MVA),该疫苗在三种动物模型(小鼠,仓鼠和恒河猴)中证明了其高安全性,强大的免疫原性和对SARS-CoV-2感染的完全有效性。本文描述了我们从大流行开始到最终实现一种非常有前途的候选疫苗的工业开发的后续步骤。下一阶段是人体临床试验。我们还讨论了其他疫苗,中长期的未来和机会。关键词:MVA;SARS-CoV-2 / COVID-19:疫苗;免疫原性;功效;动物模型
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The MVA-CoV2-S vaccine developed at the CNB-CSIC is highly immunogenic and completely effective against SARS-CoV-2/COVID-19: future and opportunities
The appearance of a new emerging virus at the end of 2019, later identified as SARS-CoV-2, which rapidly spread to the human population causing the COVID-19 pandemic (with more than 639 million people infected and more than 6.6 million deaths by November 2022), was a great challenge for science, with serious consequences for the human health system and global economy. In record time, different types of vaccines were produced that demonstrated their safety and efficacy in clinical trials and whose administration to the population has been essential for curbing the pandemic, avoiding infections, hospitalizations and deaths. Our laboratory at the CNB-CSIC has been very active in this race, generating a vaccine candidate based on the poxvirus vector termed modified vaccinia virus Ankara (MVA), which demonstrated in three animal models (mouse, hamster and rhesus macaque) its high safety, robust immunogenicity and full efficacy against SARS-CoV-2 infection. This article describes the steps that we follow it up from the beginning of the pandemic to culminate in the industrial development of a very promising vaccine candidate. The next phase is clinical trials in humans. We also discuss about other vaccines, future and opportunities in the medium-long term. Keywords: MVA; SARS-CoV-2/COVID-19: vaccine; immunogenicity; efficacy; animal models
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.13
自引率
0.00%
发文量
7
期刊介绍: The Anales de la Real Academia Nacional de Farmacia� embraces all aspects of pharmaceutical sciences and is a quarterly journal that publishes basic and applied research on pharmaceutical sciences and related areas. It is a medium for reporting selected original and significant contributions to new pharmaceutical knowledge.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信